Zevra Therapeutics, Inc. is a dynamic biopharmaceutical company located in Celebration, Florida, dedicated to the development of next-generation prodrugs targeting rare diseases where treatment options are limited. Leveraging its proprietary technology, Zevra seeks to enhance therapeutic efficacy and optimize patient outcomes, thereby establishing itself as a frontrunner in the rare disease sector. With a robust and expanding pipeline of innovative therapeutic candidates designed to tackle serious medical challenges, Zevra Therapeutics is well-positioned to drive meaningful advancements in patient care and create substantial value for institutional investors. Show more

Location: 1180 CELEBRATION BOULEVARD, CELEBRATION, FL, UNITED STATES, 34747, Celebration, FL, 34747, USA | Website: https://zevra.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

470.6M

52 Wk Range

$6.19 - $13.16

Previous Close

$8.36

Open

$8.53

Volume

604,340

Day Range

$8.48 - $8.74

Enterprise Value

367.6M

Cash

54.44M

Avg Qtr Burn

N/A

Insider Ownership

1.30%

Institutional Own.

72.73%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APADAZ (benzhydrocodone and acetaminophen) Details Acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olpruva/Sodium Phenylbutyrate (Nitrogen Scavenger) Details Urea Cycle Disorders	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AZSTARYS (KP415) (serdexmethylphenidate and dexmethylphenidate) Details Attention deficit hyperactivity disorder	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MIPLYFFA™ (arimoclomol) Details Rare genetic disease, Rare diseases, Niemann Pick Disease Type C	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Celiprolol Details Vascular Ehlers-Danlos Syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KP1077 (serdexmethylphenidate, SDX) Details EDS in Idiopathic Hypersomnia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KP879 (Methylphenidate) Details Stimulant Use Disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KP1077 (serdexmethylphenidate, SDX) Details Narcolepsy, Sleeping disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.